Quince Therapeutics, Inc. (QNCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -0.487x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.63 Million) by net assets ($15.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quince Therapeutics, Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quince Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Austin Gold Corp
NYSE MKT:AUST
|
-0.013x |
|
GR.SOU.COP. LS-01
F:E9E
|
N/A |
|
Rackla Metals Inc
V:RAK
|
-0.294x |
|
Monami
KO:005360
|
0.063x |
|
Reko International Group Inc
V:REKO
|
-0.017x |
|
SenzaGen AB
ST:SENZA
|
-0.052x |
|
IVP Limited
NSE:IVP
|
0.067x |
|
LL Lucky Games publ AB
ST:LADYLU
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Quince Therapeutics, Inc. (QNCX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.71 Million | $-41.42 Million | 1.160x | +209.60% |
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more